Johnson & Johnson, the pharmaceutical and biotech company, has spent years trying to put its talc legal issues behind it. Its latest attempt just failed again.The stock had fallen 5.3% to $157.04 in early trading Tuesday after a bankruptcy judge in Texas rejected a proposal that would have ended current and future lawsuits related to the talc products’ alleged links to cancer.

Johnson & Johnson shares fell more than 3% on Tuesday after a U.S. bankruptcy judge rejected its $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer.

A federal bankruptcy judge in Houston on Monday rejected Johnson & Johnson’s request to approve a $9 billion settlement with tens of thousands of people who are suing the company over claims that its talcum powder products caused cancer.